bluebird bio

Digital

Bringing gene therapies to market

Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need

News

bluebird claims first approval for gene therapy Zynteglo in ...

bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia.

Market Access

pharmaphorum podcast bluebird bio Nicola Redfern

Gene therapy and market access: the pharmaphorum podcast

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK.

Digital

Deep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he

News

bluebird bio gets CHMP nod for gene therapy Zynteglo

A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy for thalassemia, a rare blood disorder.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Gene addition – a new chapter in treating rare diseases

The scientific advancements of the past 30 years have transformed our understanding of the potential of gene therapy and how it may be used to tackle rare diseases.